Tl-201 decays by electron capture and gamma emission with a half-life of 3.04 days. It is typically produced in cyclotrons by bombarding thallium-203 with protons. The resulting Tl-201 is then chemically separated and incorporated into radiopharmaceuticals. Supply chain considerations involve the availability of cyclotrons, thallium targets, and radiochemistry facilities. Logistical challenges include the transport and delivery of Tl-201 radiopharmaceuticals. Accessibility for developing countries is influenced by the high cost and technical expertise required for production and handling.
Overview
Maturity
Tl-201 production and application are well-established, with widespread use in nuclear cardiology.
Safety considerations
Tl-201 is a radioactive isotope that emits gamma radiation, requiring careful handling procedures and physical shielding to minimise radiation exposure.
Security considerations
All radioactive isotopes can be misused, and as such, robust security protocols around chain of custody, inventory management, and physical security are critical.
Safeguarding considerations
Due to the absence of nuclear materials, IAEA safeguards are not applicable.
